EE43 Budget Impact Analysis of Favipiravir (AVIGAN®) for the Treatment of Patients with Confirmed Infection with SARS-COV2 in Mexico
Jul 1, 2022, 00:00 AM
10.1016/j.jval.2022.04.295
https://www.valueinhealthjournal.com/article/S1098-3015(22)00496-X/fulltext
Section Title :
Section Order :
10259
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)00496-X&doi=10.1016/j.jval.2022.04.295